MedPath
Found 1 clinical trials|View Analysis
Sort by:

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Phase 3
Recruiting
Conditions
Prostate Cancer
Interventions
Drug: Leuprolide, Degarelix or Relugolix
Radiation: Stereotactic body radiation therapy/radiosurgery (SBRT)
First Posted Date
2024-05-03
Last Posted Date
2024-05-03
Lead Sponsor
NYU Langone Health
Target Recruit Count
392
Registration Number
NCT06397703
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath